| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SCLX | Common Stock | Other | $23.5K | +2.73K | $8.60 | 2.73K | Mar 17, 2023 | By BioVintage, Inc. | F1, F2 | |
| holding | SCLX | Common Stock | 603K | Mar 17, 2023 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of common stock, par value $0.0001 per share, of the Issuer ("Scilex Common Stock") for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The Reporting Person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,730 shares of Scilex Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Scilex Common Stock. |
| F2 | (continued from footnote 1) The Put Option settled on March 17, 2023 and resulted in the Reporting Person acquiring 2,730 shares of Scilex Common Stock at a price of $8.6002 per share of Scilex Common Stock, in addition to 19,500 shares of Sorrento Common Stock at a price of $0.80268 per share of Sorrento Common Stock. |
| F3 | As a result of the Dividend, the Reporting Person received 603,298 shares of Scilex Common Stock on January 19, 2023. Shares received pursuant to the Dividend were not previously reported as they were acquired in a transaction exempt under Rule 16a-9(a) of the Securities Exchange Act of 1934, as amended. |